Relevance of molecular alterations in histopathologic subtyping of lung adenocarcinoma based on 2011 international multidisciplinary lung adenocarcinoma classification

Chinese Journal of Pathology

Volumn 41, Issue 8, 2012, Pages 505-510

  Liu, Biao ^a   Shi, Shan Shan ^a   Wang, Xuan ^a   Xu, Yan ^a   Zhng, Xin Hua ^a   Yu, Ho ^a   Lu, Zhen Feng ^a   Wang, Jian Dong ^a   Zhou, Xiao Jun ^a  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

Author keywords

Adenocarcinoma; Epidermal growth factor; Lung neoplasms; Receptor

Indexed keywords

DNA BINDING PROTEIN; EGFR PROTEIN, HUMAN; EML4 ALK FUSION PROTEIN, HUMAN; EML4-ALK FUSION PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; KRAS PROTEIN, HUMAN; ONCOPROTEIN; RAS PROTEIN; TTF1 PROTEIN, HUMAN;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; CLASSIFICATION; CODON; EXON; FEMALE; GENETICS; HUMAN; LUNG TUMOR; MALE; MEDICAL SOCIETY; METABOLISM; MIDDLE AGED; MUTATION; PATHOLOGY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CODON; DNA-BINDING PROTEINS; EXONS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; ONCOGENE PROTEINS, FUSION; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SOCIETIES, MEDICAL; YOUNG ADULT;

EID: 84866542321     PISSN: 05295807     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0529-5807.2012.08.001     Document Type: Article

References (16)

1. Travis WD, Brambilla E, Noguchi M, et al. International association for the study of lung cancer/American thoracic society/ European respiratory society internaltional multidisciplinary classification of lung adenocarcinoma. J Thoracic Oncol, 2011, 6 (2): 244-285.
2. Yoshizawa A, Motoi N, Riely GJ, et al. Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma; prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases. Mod Pathol, 2011, 24 (5): 653-664.
3. Russell PA, Wainer Z, Wright GM, et al. Does lung adenocarcinoma subtype predict patient survival?; a clinicopathologic study based on the new international association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary lung adenocarcinoma classification. J Thorac Oncol, 2011, 6(9) : 1496-1504.
4. Motoi N, Szoke J, Riely GJ, et al. Lung adenocarcinoma; modification of the 2004 WHO Mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis. Am J Surg Pathol, 2008, 32(6) : 810827.
5. Marchetti A, Buttitta F, Pellegrini S, et al. Bronchioloalveolar lung carcinomas; KRAS mutations are constant events in the mucinous subtype. J Pathol, 1996, 179(3) : 254-259.
6. Travis WD, Brambilla E, Muller-Hermelink HK, et al. World Health Organisation classification of tumours. Pathology and genetics; tumours of the lung, pleura, thymus and heart Lyon; IARC Press, 2004.
7. Yatabe Y, Kosaka T, Takahashi T, et al. EGFR mutation is specific for terminal respiratory unit type adenocarcinoma. Am J Surg Pathol, 2005, 29(5):633-639. (Pubitemid 40577873)
8. Yatabe Y. EGFR mutations and the terminal respiratory unit. Cancer Metastasis Rev, 2010, 29 (1) : 23-36.
9. Shaw AT, Yeap BY, Mino-Kenudson M, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol, 2009, 27(26) :4247-4253.
10. Yoshida A, Tsuta K, Watanabe SI, et al. Frequent ALK rearrangement and TTF-l/p63 co-expression in lung adenocarcinoma with signet-ring cell component. Lung Cancer, 2011,72(3) :309-315.
11. Pao W, Girard N. New driver mutations in non-small-cell lung cancer. Lancet Oncol, 2011, 12(2): 175-180.
12. Li C, Fang R, Sun Y, et al. Spectrum of oncogenic driver mutations in lung adenocarcinomas from east asian never smokers. PLoS One, 2011, 6(11) :e28204.
13. Okayama H, Kohno T, lshii Y, et al. Identification of genes upregulated in ALK-positive and EGFR/KRAS/ALK-negative lung adenocarcinomas. Cancer Res, 2012, 72 (1) :100-111.
14. Kohno T, Ichikawa H, Totoki Y, et al. KIF5B-RET fusions in lung adenocarcinoma. Nat Med, 2012, 18(3) : 375-377.
15. Takeuchi K, Soda M, Togashi Y, et al. RET, ROSI and ALK fusions in lung cancer. Nat Med, 2012, 18(3):378-381.
16. Ju YS, Lee WC, Shin JY, et al. A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing. Genome Res, 2012, 22(3) : 436-445.